nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—CTSK—osteoporosis	0.568	1	CbGaD
Boceprevir—ABCB1—Ethinyl Estradiol—osteoporosis	0.0174	0.118	CbGbCtD
Boceprevir—CYP3A5—Estradiol—osteoporosis	0.0172	0.117	CbGbCtD
Boceprevir—CYP3A4—Estropipate—osteoporosis	0.0161	0.109	CbGbCtD
Boceprevir—CYP3A4—Calcitriol—osteoporosis	0.0161	0.109	CbGbCtD
Boceprevir—CYP3A4—Ergocalciferol—osteoporosis	0.0129	0.0875	CbGbCtD
Boceprevir—ABCB1—Conjugated Estrogens—osteoporosis	0.0127	0.0864	CbGbCtD
Boceprevir—ABCB1—Estradiol—osteoporosis	0.0112	0.0758	CbGbCtD
Boceprevir—CYP3A4—Raloxifene—osteoporosis	0.0108	0.073	CbGbCtD
Boceprevir—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0104	0.0705	CbGbCtD
Boceprevir—CTSK—periosteum—osteoporosis	0.00937	0.351	CbGeAlD
Boceprevir—CYP3A4—Cholecalciferol—osteoporosis	0.00832	0.0564	CbGbCtD
Boceprevir—CTSK—skull—osteoporosis	0.0077	0.288	CbGeAlD
Boceprevir—CYP3A4—Conjugated Estrogens—osteoporosis	0.00764	0.0518	CbGbCtD
Boceprevir—CYP3A4—Estradiol—osteoporosis	0.00671	0.0454	CbGbCtD
Boceprevir—Telaprevir—CTSK—osteoporosis	0.0053	1	CrCbGaD
Boceprevir—CTSL—uterus—osteoporosis	0.0017	0.0637	CbGeAlD
Boceprevir—CMA1—bone marrow—osteoporosis	0.00169	0.0632	CbGeAlD
Boceprevir—CTSL—bone marrow—osteoporosis	0.00144	0.054	CbGeAlD
Boceprevir—CTSK—uterus—osteoporosis	0.00128	0.048	CbGeAlD
Boceprevir—CTSK—Estradiol—Estropipate—osteoporosis	0.00121	0.418	CbGdCrCtD
Boceprevir—CTSS—uterus—osteoporosis	0.00112	0.042	CbGeAlD
Boceprevir—CTSK—bone marrow—osteoporosis	0.00109	0.0407	CbGeAlD
Boceprevir—CTSS—bone marrow—osteoporosis	0.000953	0.0357	CbGeAlD
Boceprevir—CTSK—Estradiol—Conjugated Estrogens—osteoporosis	0.000917	0.317	CbGdCrCtD
Boceprevir—CTSK—Estradiol—Ethinyl Estradiol—osteoporosis	0.00077	0.266	CbGdCrCtD
Boceprevir—ABCB1—uterus—osteoporosis	0.000198	0.00741	CbGeAlD
Boceprevir—ABCB1—bone marrow—osteoporosis	0.000168	0.00629	CbGeAlD
Boceprevir—CMA1—Metabolism of proteins—ACE—osteoporosis	8.74e-05	0.000858	CbGpPWpGaD
Boceprevir—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	8.71e-05	0.000855	CbGpPWpGaD
Boceprevir—CTSV—Immune System—RAP1A—osteoporosis	8.61e-05	0.000845	CbGpPWpGaD
Boceprevir—CTSL—Immune System—RAP1A—osteoporosis	8.61e-05	0.000845	CbGpPWpGaD
Boceprevir—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	8.59e-05	0.000844	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ACTG1—osteoporosis	8.54e-05	0.000838	CbGpPWpGaD
Boceprevir—CTSL—Immune System—CTSK—osteoporosis	8.54e-05	0.000838	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CTSK—osteoporosis	8.54e-05	0.000838	CbGpPWpGaD
Boceprevir—CTSV—Immune System—NFATC1—osteoporosis	8.4e-05	0.000825	CbGpPWpGaD
Boceprevir—CTSL—Immune System—NFATC1—osteoporosis	8.4e-05	0.000825	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—KL—osteoporosis	8.26e-05	0.000811	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MGLL—osteoporosis	7.96e-05	0.000782	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—KL—osteoporosis	7.93e-05	0.000778	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—AGER—osteoporosis	7.83e-05	0.000769	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—AGER—osteoporosis	7.83e-05	0.000769	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—ADCY5—osteoporosis	7.81e-05	0.000766	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—ADCY5—osteoporosis	7.81e-05	0.000766	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—LRP5—osteoporosis	7.77e-05	0.000763	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—PSMA5—osteoporosis	7.72e-05	0.000758	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—PSMA2—osteoporosis	7.72e-05	0.000758	CbGpPWpGaD
Boceprevir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	7.71e-05	0.000757	CbGpPWpGaD
Boceprevir—CTSL—Toll-Like Receptors Cascades—IL6—osteoporosis	7.7e-05	0.000756	CbGpPWpGaD
Boceprevir—CTSV—Toll-Like Receptors Cascades—IL6—osteoporosis	7.7e-05	0.000756	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IRAK3—osteoporosis	7.69e-05	0.000755	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	7.62e-05	0.000748	CbGpPWpGaD
Boceprevir—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	7.61e-05	0.000747	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—LRP6—osteoporosis	7.44e-05	0.00073	CbGpPWpGaD
Boceprevir—Anxiety—Zoledronate—osteoporosis	7.39e-05	0.000499	CcSEcCtD
Boceprevir—Loss of consciousness—Conjugated Estrogens—osteoporosis	7.37e-05	0.000498	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	7.37e-05	0.000498	CcSEcCtD
Boceprevir—Paraesthesia—Risedronate—osteoporosis	7.35e-05	0.000497	CcSEcCtD
Boceprevir—Pruritus—Estropipate—osteoporosis	7.33e-05	0.000495	CcSEcCtD
Boceprevir—Discomfort—Zoledronate—osteoporosis	7.33e-05	0.000495	CcSEcCtD
Boceprevir—Asthenia—Alendronate—osteoporosis	7.32e-05	0.000495	CcSEcCtD
Boceprevir—Hypersensitivity—Ibandronate—osteoporosis	7.32e-05	0.000494	CcSEcCtD
Boceprevir—Cough—Conjugated Estrogens—osteoporosis	7.32e-05	0.000494	CcSEcCtD
Boceprevir—Dyspnoea—Risedronate—osteoporosis	7.3e-05	0.000493	CcSEcCtD
Boceprevir—Erythema multiforme—Estradiol—osteoporosis	7.29e-05	0.000493	CcSEcCtD
Boceprevir—Hypotension—Pamidronate—osteoporosis	7.27e-05	0.000491	CcSEcCtD
Boceprevir—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	7.26e-05	0.000713	CbGpPWpGaD
Boceprevir—Dry mouth—Zoledronate—osteoporosis	7.25e-05	0.00049	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	7.25e-05	0.00049	CcSEcCtD
Boceprevir—Fatigue—Ethinyl Estradiol—osteoporosis	7.24e-05	0.000489	CcSEcCtD
Boceprevir—Pruritus—Alendronate—osteoporosis	7.22e-05	0.000488	CcSEcCtD
Boceprevir—Dyspepsia—Risedronate—osteoporosis	7.21e-05	0.000487	CcSEcCtD
Boceprevir—Eye disorder—Estradiol—osteoporosis	7.21e-05	0.000487	CcSEcCtD
Boceprevir—Tinnitus—Estradiol—osteoporosis	7.19e-05	0.000486	CcSEcCtD
Boceprevir—Constipation—Ethinyl Estradiol—osteoporosis	7.18e-05	0.000485	CcSEcCtD
Boceprevir—Confusional state—Zoledronate—osteoporosis	7.17e-05	0.000484	CcSEcCtD
Boceprevir—Hypersensitivity—Calcitriol—osteoporosis	7.17e-05	0.000484	CcSEcCtD
Boceprevir—CMA1—Signaling by SCF-KIT—IL6—osteoporosis	7.16e-05	0.000703	CbGpPWpGaD
Boceprevir—Flushing—Estradiol—osteoporosis	7.16e-05	0.000483	CcSEcCtD
Boceprevir—Cardiac disorder—Estradiol—osteoporosis	7.16e-05	0.000483	CcSEcCtD
Boceprevir—Myalgia—Conjugated Estrogens—osteoporosis	7.14e-05	0.000482	CcSEcCtD
Boceprevir—Chest pain—Conjugated Estrogens—osteoporosis	7.14e-05	0.000482	CcSEcCtD
Boceprevir—Arthralgia—Conjugated Estrogens—osteoporosis	7.14e-05	0.000482	CcSEcCtD
Boceprevir—CYP3A5—Biological oxidations—CYP27A1—osteoporosis	7.14e-05	0.000701	CbGpPWpGaD
Boceprevir—CTSK—Immune System—RAP1A—osteoporosis	7.13e-05	0.000701	CbGpPWpGaD
Boceprevir—Asthenia—Ibandronate—osteoporosis	7.13e-05	0.000482	CcSEcCtD
Boceprevir—Anxiety—Conjugated Estrogens—osteoporosis	7.12e-05	0.000481	CcSEcCtD
Boceprevir—Nausea—Etidronic acid—osteoporosis	7.11e-05	0.000481	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	7.09e-05	0.000479	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Pamidronate—osteoporosis	7.09e-05	0.000479	CcSEcCtD
Boceprevir—Diarrhoea—Estropipate—osteoporosis	7.09e-05	0.000479	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Risedronate—osteoporosis	7.07e-05	0.000478	CcSEcCtD
Boceprevir—Infection—Zoledronate—osteoporosis	7.06e-05	0.000477	CcSEcCtD
Boceprevir—Fatigue—Risedronate—osteoporosis	7.06e-05	0.000477	CcSEcCtD
Boceprevir—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.06e-05	0.000693	CbGpPWpGaD
Boceprevir—Insomnia—Pamidronate—osteoporosis	7.04e-05	0.000476	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP27A1—osteoporosis	7.04e-05	0.000691	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ACTG1—osteoporosis	7.03e-05	0.00069	CbGpPWpGaD
Boceprevir—Pruritus—Ibandronate—osteoporosis	7.03e-05	0.000475	CcSEcCtD
Boceprevir—Constipation—Risedronate—osteoporosis	7e-05	0.000473	CcSEcCtD
Boceprevir—Pain—Risedronate—osteoporosis	7e-05	0.000473	CcSEcCtD
Boceprevir—Angiopathy—Estradiol—osteoporosis	7e-05	0.000473	CcSEcCtD
Boceprevir—Shock—Zoledronate—osteoporosis	7e-05	0.000473	CcSEcCtD
Boceprevir—Paraesthesia—Pamidronate—osteoporosis	6.99e-05	0.000472	CcSEcCtD
Boceprevir—Diarrhoea—Alendronate—osteoporosis	6.98e-05	0.000472	CcSEcCtD
Boceprevir—Asthenia—Calcitriol—osteoporosis	6.98e-05	0.000471	CcSEcCtD
Boceprevir—Nervous system disorder—Zoledronate—osteoporosis	6.97e-05	0.000471	CcSEcCtD
Boceprevir—Immune system disorder—Estradiol—osteoporosis	6.97e-05	0.000471	CcSEcCtD
Boceprevir—Thrombocytopenia—Zoledronate—osteoporosis	6.96e-05	0.00047	CcSEcCtD
Boceprevir—CTSK—Immune System—NFATC1—osteoporosis	6.96e-05	0.000683	CbGpPWpGaD
Boceprevir—Mediastinal disorder—Estradiol—osteoporosis	6.95e-05	0.00047	CcSEcCtD
Boceprevir—Dyspnoea—Pamidronate—osteoporosis	6.94e-05	0.000469	CcSEcCtD
Boceprevir—Tachycardia—Zoledronate—osteoporosis	6.94e-05	0.000469	CcSEcCtD
Boceprevir—Feeling abnormal—Ethinyl Estradiol—osteoporosis	6.92e-05	0.000467	CcSEcCtD
Boceprevir—Chills—Estradiol—osteoporosis	6.92e-05	0.000467	CcSEcCtD
Boceprevir—Skin disorder—Zoledronate—osteoporosis	6.91e-05	0.000467	CcSEcCtD
Boceprevir—Pruritus—Calcitriol—osteoporosis	6.88e-05	0.000465	CcSEcCtD
Boceprevir—Hyperhidrosis—Zoledronate—osteoporosis	6.87e-05	0.000464	CcSEcCtD
Boceprevir—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	6.87e-05	0.000464	CcSEcCtD
Boceprevir—Diarrhoea—Raloxifene—osteoporosis	6.87e-05	0.000464	CcSEcCtD
Boceprevir—CTSV—Immune System—PSMA5—osteoporosis	6.86e-05	0.000673	CbGpPWpGaD
Boceprevir—CTSV—Immune System—PSMA2—osteoporosis	6.86e-05	0.000673	CbGpPWpGaD
Boceprevir—CTSL—Immune System—PSMA2—osteoporosis	6.86e-05	0.000673	CbGpPWpGaD
Boceprevir—CTSL—Immune System—PSMA5—osteoporosis	6.86e-05	0.000673	CbGpPWpGaD
Boceprevir—Dyspepsia—Pamidronate—osteoporosis	6.85e-05	0.000463	CcSEcCtD
Boceprevir—Dizziness—Estropipate—osteoporosis	6.85e-05	0.000463	CcSEcCtD
Boceprevir—CTSL—Innate Immune System—IRS2—osteoporosis	6.83e-05	0.000671	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—IRS2—osteoporosis	6.83e-05	0.000671	CbGpPWpGaD
Boceprevir—Alopecia—Estradiol—osteoporosis	6.82e-05	0.00046	CcSEcCtD
Boceprevir—Infection—Conjugated Estrogens—osteoporosis	6.8e-05	0.000459	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—KL—osteoporosis	6.8e-05	0.000668	CbGpPWpGaD
Boceprevir—Diarrhoea—Ibandronate—osteoporosis	6.8e-05	0.000459	CcSEcCtD
Boceprevir—Decreased appetite—Pamidronate—osteoporosis	6.77e-05	0.000457	CcSEcCtD
Boceprevir—Mental disorder—Estradiol—osteoporosis	6.76e-05	0.000456	CcSEcCtD
Boceprevir—Dizziness—Alendronate—osteoporosis	6.75e-05	0.000456	CcSEcCtD
Boceprevir—Shock—Conjugated Estrogens—osteoporosis	6.74e-05	0.000455	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Pamidronate—osteoporosis	6.72e-05	0.000454	CcSEcCtD
Boceprevir—Nervous system disorder—Conjugated Estrogens—osteoporosis	6.71e-05	0.000454	CcSEcCtD
Boceprevir—Erythema—Estradiol—osteoporosis	6.71e-05	0.000454	CcSEcCtD
Boceprevir—Malnutrition—Estradiol—osteoporosis	6.71e-05	0.000454	CcSEcCtD
Boceprevir—Fatigue—Pamidronate—osteoporosis	6.71e-05	0.000453	CcSEcCtD
Boceprevir—Gastrointestinal pain—Risedronate—osteoporosis	6.7e-05	0.000452	CcSEcCtD
Boceprevir—Tachycardia—Conjugated Estrogens—osteoporosis	6.68e-05	0.000451	CcSEcCtD
Boceprevir—Urticaria—Ethinyl Estradiol—osteoporosis	6.67e-05	0.000451	CcSEcCtD
Boceprevir—Pain—Pamidronate—osteoporosis	6.66e-05	0.00045	CcSEcCtD
Boceprevir—Constipation—Pamidronate—osteoporosis	6.66e-05	0.00045	CcSEcCtD
Boceprevir—Diarrhoea—Calcitriol—osteoporosis	6.66e-05	0.00045	CcSEcCtD
Boceprevir—Skin disorder—Conjugated Estrogens—osteoporosis	6.65e-05	0.000449	CcSEcCtD
Boceprevir—Hypotension—Zoledronate—osteoporosis	6.64e-05	0.000449	CcSEcCtD
Boceprevir—Abdominal pain—Ethinyl Estradiol—osteoporosis	6.64e-05	0.000448	CcSEcCtD
Boceprevir—Body temperature increased—Ethinyl Estradiol—osteoporosis	6.64e-05	0.000448	CcSEcCtD
Boceprevir—Dizziness—Raloxifene—osteoporosis	6.64e-05	0.000448	CcSEcCtD
Boceprevir—Hyperhidrosis—Conjugated Estrogens—osteoporosis	6.62e-05	0.000447	CcSEcCtD
Boceprevir—Flatulence—Estradiol—osteoporosis	6.62e-05	0.000447	CcSEcCtD
Boceprevir—Vomiting—Estropipate—osteoporosis	6.59e-05	0.000445	CcSEcCtD
Boceprevir—Dysgeusia—Estradiol—osteoporosis	6.57e-05	0.000444	CcSEcCtD
Boceprevir—Dizziness—Ibandronate—osteoporosis	6.57e-05	0.000444	CcSEcCtD
Boceprevir—CTSV—Adaptive Immune System—IRS2—osteoporosis	6.56e-05	0.000644	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—IRS2—osteoporosis	6.56e-05	0.000644	CbGpPWpGaD
Boceprevir—Rash—Estropipate—osteoporosis	6.53e-05	0.000441	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—KL—osteoporosis	6.53e-05	0.000641	CbGpPWpGaD
Boceprevir—Dermatitis—Estropipate—osteoporosis	6.53e-05	0.000441	CcSEcCtD
Boceprevir—Urticaria—Risedronate—osteoporosis	6.51e-05	0.000439	CcSEcCtD
Boceprevir—Back pain—Estradiol—osteoporosis	6.49e-05	0.000439	CcSEcCtD
Boceprevir—Headache—Estropipate—osteoporosis	6.49e-05	0.000438	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—AGER—osteoporosis	6.49e-05	0.000637	CbGpPWpGaD
Boceprevir—Vomiting—Alendronate—osteoporosis	6.49e-05	0.000438	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Zoledronate—osteoporosis	6.48e-05	0.000438	CcSEcCtD
Boceprevir—Abdominal pain—Risedronate—osteoporosis	6.47e-05	0.000437	CcSEcCtD
Boceprevir—Body temperature increased—Risedronate—osteoporosis	6.47e-05	0.000437	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—ADCY5—osteoporosis	6.47e-05	0.000635	CbGpPWpGaD
Boceprevir—Muscle spasms—Estradiol—osteoporosis	6.46e-05	0.000436	CcSEcCtD
Boceprevir—Rash—Alendronate—osteoporosis	6.43e-05	0.000435	CcSEcCtD
Boceprevir—Insomnia—Zoledronate—osteoporosis	6.43e-05	0.000434	CcSEcCtD
Boceprevir—Dermatitis—Alendronate—osteoporosis	6.43e-05	0.000434	CcSEcCtD
Boceprevir—Feeling abnormal—Pamidronate—osteoporosis	6.41e-05	0.000433	CcSEcCtD
Boceprevir—Hypotension—Conjugated Estrogens—osteoporosis	6.4e-05	0.000432	CcSEcCtD
Boceprevir—Headache—Alendronate—osteoporosis	6.39e-05	0.000432	CcSEcCtD
Boceprevir—Paraesthesia—Zoledronate—osteoporosis	6.38e-05	0.000431	CcSEcCtD
Boceprevir—CTSK—Toll-Like Receptors Cascades—IL6—osteoporosis	6.38e-05	0.000627	CbGpPWpGaD
Boceprevir—Vomiting—Raloxifene—osteoporosis	6.38e-05	0.000431	CcSEcCtD
Boceprevir—Gastrointestinal pain—Pamidronate—osteoporosis	6.37e-05	0.00043	CcSEcCtD
Boceprevir—Dyspnoea—Zoledronate—osteoporosis	6.34e-05	0.000428	CcSEcCtD
Boceprevir—Rash—Raloxifene—osteoporosis	6.33e-05	0.000427	CcSEcCtD
Boceprevir—Dermatitis—Raloxifene—osteoporosis	6.32e-05	0.000427	CcSEcCtD
Boceprevir—Vomiting—Ibandronate—osteoporosis	6.32e-05	0.000427	CcSEcCtD
Boceprevir—Headache—Raloxifene—osteoporosis	6.29e-05	0.000425	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—TLN1—osteoporosis	6.28e-05	0.000616	CbGpPWpGaD
Boceprevir—Rash—Ibandronate—osteoporosis	6.27e-05	0.000423	CcSEcCtD
Boceprevir—Dermatitis—Ibandronate—osteoporosis	6.26e-05	0.000423	CcSEcCtD
Boceprevir—Dyspepsia—Zoledronate—osteoporosis	6.26e-05	0.000423	CcSEcCtD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	6.25e-05	0.000613	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	6.24e-05	0.000421	CcSEcCtD
Boceprevir—Ill-defined disorder—Estradiol—osteoporosis	6.23e-05	0.000421	CcSEcCtD
Boceprevir—Headache—Ibandronate—osteoporosis	6.22e-05	0.00042	CcSEcCtD
Boceprevir—Insomnia—Conjugated Estrogens—osteoporosis	6.19e-05	0.000418	CcSEcCtD
Boceprevir—CTSV—Extracellular matrix organization—TGFB1—osteoporosis	6.19e-05	0.000608	CbGpPWpGaD
Boceprevir—CTSL—Extracellular matrix organization—TGFB1—osteoporosis	6.19e-05	0.000608	CbGpPWpGaD
Boceprevir—Hypersensitivity—Ethinyl Estradiol—osteoporosis	6.19e-05	0.000418	CcSEcCtD
Boceprevir—Vomiting—Calcitriol—osteoporosis	6.18e-05	0.000418	CcSEcCtD
Boceprevir—Decreased appetite—Zoledronate—osteoporosis	6.18e-05	0.000418	CcSEcCtD
Boceprevir—Agitation—Estradiol—osteoporosis	6.17e-05	0.000417	CcSEcCtD
Boceprevir—Nausea—Estropipate—osteoporosis	6.15e-05	0.000416	CcSEcCtD
Boceprevir—Abdominal pain—Pamidronate—osteoporosis	6.15e-05	0.000416	CcSEcCtD
Boceprevir—Body temperature increased—Pamidronate—osteoporosis	6.15e-05	0.000416	CcSEcCtD
Boceprevir—Paraesthesia—Conjugated Estrogens—osteoporosis	6.15e-05	0.000415	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Zoledronate—osteoporosis	6.14e-05	0.000415	CcSEcCtD
Boceprevir—Angioedema—Estradiol—osteoporosis	6.13e-05	0.000414	CcSEcCtD
Boceprevir—Rash—Calcitriol—osteoporosis	6.13e-05	0.000414	CcSEcCtD
Boceprevir—Fatigue—Zoledronate—osteoporosis	6.13e-05	0.000414	CcSEcCtD
Boceprevir—Dermatitis—Calcitriol—osteoporosis	6.13e-05	0.000414	CcSEcCtD
Boceprevir—Dyspnoea—Conjugated Estrogens—osteoporosis	6.1e-05	0.000412	CcSEcCtD
Boceprevir—Headache—Calcitriol—osteoporosis	6.09e-05	0.000412	CcSEcCtD
Boceprevir—Pain—Zoledronate—osteoporosis	6.08e-05	0.000411	CcSEcCtD
Boceprevir—Constipation—Zoledronate—osteoporosis	6.08e-05	0.000411	CcSEcCtD
Boceprevir—Nausea—Alendronate—osteoporosis	6.06e-05	0.000409	CcSEcCtD
Boceprevir—Malaise—Estradiol—osteoporosis	6.05e-05	0.000409	CcSEcCtD
Boceprevir—Hypersensitivity—Risedronate—osteoporosis	6.03e-05	0.000408	CcSEcCtD
Boceprevir—Vertigo—Estradiol—osteoporosis	6.03e-05	0.000407	CcSEcCtD
Boceprevir—Dyspepsia—Conjugated Estrogens—osteoporosis	6.03e-05	0.000407	CcSEcCtD
Boceprevir—Asthenia—Ethinyl Estradiol—osteoporosis	6.03e-05	0.000407	CcSEcCtD
Boceprevir—Syncope—Estradiol—osteoporosis	6.02e-05	0.000407	CcSEcCtD
Boceprevir—CTSV—Innate Immune System—IRS1—osteoporosis	5.96e-05	0.000585	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—IRS1—osteoporosis	5.96e-05	0.000585	CbGpPWpGaD
Boceprevir—Nausea—Raloxifene—osteoporosis	5.96e-05	0.000403	CcSEcCtD
Boceprevir—Decreased appetite—Conjugated Estrogens—osteoporosis	5.95e-05	0.000402	CcSEcCtD
Boceprevir—Pruritus—Ethinyl Estradiol—osteoporosis	5.94e-05	0.000401	CcSEcCtD
Boceprevir—Palpitations—Estradiol—osteoporosis	5.93e-05	0.000401	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	5.91e-05	0.000399	CcSEcCtD
Boceprevir—Fatigue—Conjugated Estrogens—osteoporosis	5.9e-05	0.000399	CcSEcCtD
Boceprevir—Nausea—Ibandronate—osteoporosis	5.9e-05	0.000399	CcSEcCtD
Boceprevir—Loss of consciousness—Estradiol—osteoporosis	5.9e-05	0.000399	CcSEcCtD
Boceprevir—CTSS—Immune System—RAP1A—osteoporosis	5.88e-05	0.000577	CbGpPWpGaD
Boceprevir—Asthenia—Risedronate—osteoporosis	5.88e-05	0.000397	CcSEcCtD
Boceprevir—Feeling abnormal—Zoledronate—osteoporosis	5.86e-05	0.000396	CcSEcCtD
Boceprevir—Cough—Estradiol—osteoporosis	5.86e-05	0.000396	CcSEcCtD
Boceprevir—Constipation—Conjugated Estrogens—osteoporosis	5.85e-05	0.000395	CcSEcCtD
Boceprevir—Pain—Conjugated Estrogens—osteoporosis	5.85e-05	0.000395	CcSEcCtD
Boceprevir—CTSS—Immune System—CTSK—osteoporosis	5.83e-05	0.000572	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Zoledronate—osteoporosis	5.81e-05	0.000393	CcSEcCtD
Boceprevir—CTSV—Immune System—KL—osteoporosis	5.8e-05	0.00057	CbGpPWpGaD
Boceprevir—CTSL—Immune System—KL—osteoporosis	5.8e-05	0.00057	CbGpPWpGaD
Boceprevir—Hypertension—Estradiol—osteoporosis	5.8e-05	0.000392	CcSEcCtD
Boceprevir—Pruritus—Risedronate—osteoporosis	5.79e-05	0.000391	CcSEcCtD
Boceprevir—Nausea—Calcitriol—osteoporosis	5.78e-05	0.00039	CcSEcCtD
Boceprevir—CMA1—Extracellular matrix organization—TGFB1—osteoporosis	5.75e-05	0.000565	CbGpPWpGaD
Boceprevir—Diarrhoea—Ethinyl Estradiol—osteoporosis	5.75e-05	0.000388	CcSEcCtD
Boceprevir—Hypersensitivity—Pamidronate—osteoporosis	5.74e-05	0.000387	CcSEcCtD
Boceprevir—CTSS—Immune System—NFATC1—osteoporosis	5.73e-05	0.000563	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—IRS1—osteoporosis	5.73e-05	0.000562	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—IRS1—osteoporosis	5.73e-05	0.000562	CbGpPWpGaD
Boceprevir—Arthralgia—Estradiol—osteoporosis	5.72e-05	0.000386	CcSEcCtD
Boceprevir—Chest pain—Estradiol—osteoporosis	5.72e-05	0.000386	CcSEcCtD
Boceprevir—Myalgia—Estradiol—osteoporosis	5.72e-05	0.000386	CcSEcCtD
Boceprevir—Anxiety—Estradiol—osteoporosis	5.7e-05	0.000385	CcSEcCtD
Boceprevir—CTSK—Immune System—PSMA5—osteoporosis	5.68e-05	0.000558	CbGpPWpGaD
Boceprevir—CTSK—Immune System—PSMA2—osteoporosis	5.68e-05	0.000558	CbGpPWpGaD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	5.68e-05	0.000383	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—IRS2—osteoporosis	5.66e-05	0.000556	CbGpPWpGaD
Boceprevir—Urticaria—Zoledronate—osteoporosis	5.65e-05	0.000382	CcSEcCtD
Boceprevir—Discomfort—Estradiol—osteoporosis	5.65e-05	0.000381	CcSEcCtD
Boceprevir—Body temperature increased—Zoledronate—osteoporosis	5.62e-05	0.00038	CcSEcCtD
Boceprevir—Abdominal pain—Zoledronate—osteoporosis	5.62e-05	0.00038	CcSEcCtD
Boceprevir—Diarrhoea—Risedronate—osteoporosis	5.6e-05	0.000378	CcSEcCtD
Boceprevir—CTSL—Innate Immune System—IL6R—osteoporosis	5.6e-05	0.00055	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—IL6R—osteoporosis	5.6e-05	0.00055	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	5.6e-05	0.000378	CcSEcCtD
Boceprevir—Dry mouth—Estradiol—osteoporosis	5.59e-05	0.000378	CcSEcCtD
Boceprevir—Asthenia—Pamidronate—osteoporosis	5.59e-05	0.000377	CcSEcCtD
Boceprevir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	5.57e-05	0.000547	CbGpPWpGaD
Boceprevir—Dizziness—Ethinyl Estradiol—osteoporosis	5.55e-05	0.000375	CcSEcCtD
Boceprevir—Confusional state—Estradiol—osteoporosis	5.53e-05	0.000373	CcSEcCtD
Boceprevir—Pruritus—Pamidronate—osteoporosis	5.51e-05	0.000372	CcSEcCtD
Boceprevir—Infection—Estradiol—osteoporosis	5.44e-05	0.000368	CcSEcCtD
Boceprevir—Urticaria—Conjugated Estrogens—osteoporosis	5.44e-05	0.000367	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—IRS2—osteoporosis	5.43e-05	0.000534	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—LEP—osteoporosis	5.43e-05	0.000533	CbGpPWpGaD
Boceprevir—Dizziness—Risedronate—osteoporosis	5.42e-05	0.000366	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—P4HB—osteoporosis	5.41e-05	0.000532	CbGpPWpGaD
Boceprevir—Abdominal pain—Conjugated Estrogens—osteoporosis	5.41e-05	0.000366	CcSEcCtD
Boceprevir—Body temperature increased—Conjugated Estrogens—osteoporosis	5.41e-05	0.000366	CcSEcCtD
Boceprevir—Shock—Estradiol—osteoporosis	5.39e-05	0.000364	CcSEcCtD
Boceprevir—Nervous system disorder—Estradiol—osteoporosis	5.37e-05	0.000363	CcSEcCtD
Boceprevir—Tachycardia—Estradiol—osteoporosis	5.35e-05	0.000361	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—AGER—osteoporosis	5.34e-05	0.000525	CbGpPWpGaD
Boceprevir—Vomiting—Ethinyl Estradiol—osteoporosis	5.34e-05	0.000361	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—ADCY5—osteoporosis	5.33e-05	0.000523	CbGpPWpGaD
Boceprevir—Diarrhoea—Pamidronate—osteoporosis	5.33e-05	0.00036	CcSEcCtD
Boceprevir—Skin disorder—Estradiol—osteoporosis	5.32e-05	0.00036	CcSEcCtD
Boceprevir—Hyperhidrosis—Estradiol—osteoporosis	5.3e-05	0.000358	CcSEcCtD
Boceprevir—Rash—Ethinyl Estradiol—osteoporosis	5.3e-05	0.000358	CcSEcCtD
Boceprevir—Dermatitis—Ethinyl Estradiol—osteoporosis	5.29e-05	0.000357	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—PTH—osteoporosis	5.27e-05	0.000517	CbGpPWpGaD
Boceprevir—Headache—Ethinyl Estradiol—osteoporosis	5.26e-05	0.000355	CcSEcCtD
Boceprevir—CTSS—Toll-Like Receptors Cascades—IL6—osteoporosis	5.26e-05	0.000516	CbGpPWpGaD
Boceprevir—Hypersensitivity—Zoledronate—osteoporosis	5.24e-05	0.000354	CcSEcCtD
Boceprevir—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.23e-05	0.000514	CbGpPWpGaD
Boceprevir—Vomiting—Risedronate—osteoporosis	5.21e-05	0.000352	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—RAP1A—osteoporosis	5.18e-05	0.000508	CbGpPWpGaD
Boceprevir—Rash—Risedronate—osteoporosis	5.16e-05	0.000349	CcSEcCtD
Boceprevir—Dermatitis—Risedronate—osteoporosis	5.16e-05	0.000348	CcSEcCtD
Boceprevir—Dizziness—Pamidronate—osteoporosis	5.15e-05	0.000348	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—CNR2—osteoporosis	5.13e-05	0.000504	CbGpPWpGaD
Boceprevir—Headache—Risedronate—osteoporosis	5.13e-05	0.000347	CcSEcCtD
Boceprevir—CTSK—Extracellular matrix organization—TGFB1—osteoporosis	5.13e-05	0.000504	CbGpPWpGaD
Boceprevir—Asthenia—Zoledronate—osteoporosis	5.1e-05	0.000345	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—NFATC1—osteoporosis	5.05e-05	0.000496	CbGpPWpGaD
Boceprevir—Hypersensitivity—Conjugated Estrogens—osteoporosis	5.04e-05	0.000341	CcSEcCtD
Boceprevir—Pruritus—Zoledronate—osteoporosis	5.03e-05	0.00034	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—DKK1—osteoporosis	5.01e-05	0.000492	CbGpPWpGaD
Boceprevir—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	5.01e-05	0.000492	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Estradiol—osteoporosis	4.99e-05	0.000337	CcSEcCtD
Boceprevir—Nausea—Ethinyl Estradiol—osteoporosis	4.99e-05	0.000337	CcSEcCtD
Boceprevir—Insomnia—Estradiol—osteoporosis	4.96e-05	0.000335	CcSEcCtD
Boceprevir—Vomiting—Pamidronate—osteoporosis	4.95e-05	0.000334	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—IRS1—osteoporosis	4.94e-05	0.000485	CbGpPWpGaD
Boceprevir—Paraesthesia—Estradiol—osteoporosis	4.92e-05	0.000332	CcSEcCtD
Boceprevir—Asthenia—Conjugated Estrogens—osteoporosis	4.91e-05	0.000332	CcSEcCtD
Boceprevir—Rash—Pamidronate—osteoporosis	4.91e-05	0.000332	CcSEcCtD
Boceprevir—Dermatitis—Pamidronate—osteoporosis	4.9e-05	0.000331	CcSEcCtD
Boceprevir—Dyspnoea—Estradiol—osteoporosis	4.89e-05	0.00033	CcSEcCtD
Boceprevir—Headache—Pamidronate—osteoporosis	4.88e-05	0.000329	CcSEcCtD
Boceprevir—Diarrhoea—Zoledronate—osteoporosis	4.87e-05	0.000329	CcSEcCtD
Boceprevir—Nausea—Risedronate—osteoporosis	4.86e-05	0.000329	CcSEcCtD
Boceprevir—Pruritus—Conjugated Estrogens—osteoporosis	4.84e-05	0.000327	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—WNT1—osteoporosis	4.83e-05	0.000474	CbGpPWpGaD
Boceprevir—Dyspepsia—Estradiol—osteoporosis	4.82e-05	0.000326	CcSEcCtD
Boceprevir—CTSK—Immune System—KL—osteoporosis	4.81e-05	0.000472	CbGpPWpGaD
Boceprevir—Decreased appetite—Estradiol—osteoporosis	4.76e-05	0.000322	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—IRS1—osteoporosis	4.74e-05	0.000466	CbGpPWpGaD
Boceprevir—Gastrointestinal disorder—Estradiol—osteoporosis	4.73e-05	0.00032	CcSEcCtD
Boceprevir—Fatigue—Estradiol—osteoporosis	4.72e-05	0.000319	CcSEcCtD
Boceprevir—Dizziness—Zoledronate—osteoporosis	4.7e-05	0.000318	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—FGA—osteoporosis	4.69e-05	0.000461	CbGpPWpGaD
Boceprevir—Pain—Estradiol—osteoporosis	4.69e-05	0.000317	CcSEcCtD
Boceprevir—Constipation—Estradiol—osteoporosis	4.69e-05	0.000317	CcSEcCtD
Boceprevir—Diarrhoea—Conjugated Estrogens—osteoporosis	4.68e-05	0.000316	CcSEcCtD
Boceprevir—CTSS—Immune System—PSMA2—osteoporosis	4.68e-05	0.00046	CbGpPWpGaD
Boceprevir—CTSS—Immune System—PSMA5—osteoporosis	4.68e-05	0.00046	CbGpPWpGaD
Boceprevir—CMA1—Metabolism of proteins—POMC—osteoporosis	4.66e-05	0.000458	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—IRS2—osteoporosis	4.66e-05	0.000458	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—IL6R—osteoporosis	4.64e-05	0.000456	CbGpPWpGaD
Boceprevir—Nausea—Pamidronate—osteoporosis	4.62e-05	0.000312	CcSEcCtD
Boceprevir—CTSL—Immune System—AGER—osteoporosis	4.56e-05	0.000448	CbGpPWpGaD
Boceprevir—CTSV—Immune System—AGER—osteoporosis	4.56e-05	0.000448	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ADCY5—osteoporosis	4.55e-05	0.000446	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ADCY5—osteoporosis	4.55e-05	0.000446	CbGpPWpGaD
Boceprevir—Dizziness—Conjugated Estrogens—osteoporosis	4.53e-05	0.000306	CcSEcCtD
Boceprevir—Vomiting—Zoledronate—osteoporosis	4.52e-05	0.000305	CcSEcCtD
Boceprevir—Feeling abnormal—Estradiol—osteoporosis	4.52e-05	0.000305	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—IGF1—osteoporosis	4.49e-05	0.00044	CbGpPWpGaD
Boceprevir—Rash—Zoledronate—osteoporosis	4.48e-05	0.000303	CcSEcCtD
Boceprevir—Gastrointestinal pain—Estradiol—osteoporosis	4.48e-05	0.000303	CcSEcCtD
Boceprevir—Dermatitis—Zoledronate—osteoporosis	4.48e-05	0.000303	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—IRS2—osteoporosis	4.48e-05	0.000439	CbGpPWpGaD
Boceprevir—Headache—Zoledronate—osteoporosis	4.45e-05	0.000301	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—PTHLH—osteoporosis	4.36e-05	0.000428	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—BMP2—osteoporosis	4.36e-05	0.000428	CbGpPWpGaD
Boceprevir—Vomiting—Conjugated Estrogens—osteoporosis	4.35e-05	0.000294	CcSEcCtD
Boceprevir—Urticaria—Estradiol—osteoporosis	4.35e-05	0.000294	CcSEcCtD
Boceprevir—Abdominal pain—Estradiol—osteoporosis	4.33e-05	0.000293	CcSEcCtD
Boceprevir—Body temperature increased—Estradiol—osteoporosis	4.33e-05	0.000293	CcSEcCtD
Boceprevir—Rash—Conjugated Estrogens—osteoporosis	4.32e-05	0.000292	CcSEcCtD
Boceprevir—Dermatitis—Conjugated Estrogens—osteoporosis	4.31e-05	0.000291	CcSEcCtD
Boceprevir—Headache—Conjugated Estrogens—osteoporosis	4.29e-05	0.00029	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—FGB—osteoporosis	4.27e-05	0.000419	CbGpPWpGaD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	4.26e-05	0.000418	CbGpPWpGaD
Boceprevir—CYP3A5—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.24e-05	0.000417	CbGpPWpGaD
Boceprevir—Nausea—Zoledronate—osteoporosis	4.22e-05	0.000285	CcSEcCtD
Boceprevir—CTSS—Extracellular matrix organization—TGFB1—osteoporosis	4.22e-05	0.000415	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PSMA5—osteoporosis	4.12e-05	0.000405	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PSMA2—osteoporosis	4.12e-05	0.000405	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—IRS1—osteoporosis	4.07e-05	0.000399	CbGpPWpGaD
Boceprevir—Nausea—Conjugated Estrogens—osteoporosis	4.07e-05	0.000275	CcSEcCtD
Boceprevir—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	4.05e-05	0.000397	CbGpPWpGaD
Boceprevir—Hypersensitivity—Estradiol—osteoporosis	4.04e-05	0.000273	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	4.03e-05	0.000395	CbGpPWpGaD
Boceprevir—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	4e-05	0.000392	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IRS2—osteoporosis	3.98e-05	0.000391	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IRS2—osteoporosis	3.98e-05	0.000391	CbGpPWpGaD
Boceprevir—CTSS—Immune System—KL—osteoporosis	3.96e-05	0.000389	CbGpPWpGaD
Boceprevir—Asthenia—Estradiol—osteoporosis	3.93e-05	0.000266	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—IRS1—osteoporosis	3.91e-05	0.000384	CbGpPWpGaD
Boceprevir—Pruritus—Estradiol—osteoporosis	3.88e-05	0.000262	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—CALCA—osteoporosis	3.84e-05	0.000377	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—IL6R—osteoporosis	3.82e-05	0.000375	CbGpPWpGaD
Boceprevir—CTSK—Immune System—AGER—osteoporosis	3.78e-05	0.000371	CbGpPWpGaD
Boceprevir—CTSK—Immune System—ADCY5—osteoporosis	3.77e-05	0.00037	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—CYP19A1—osteoporosis	3.75e-05	0.000368	CbGpPWpGaD
Boceprevir—Diarrhoea—Estradiol—osteoporosis	3.75e-05	0.000253	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—CYP19A1—osteoporosis	3.7e-05	0.000363	CbGpPWpGaD
Boceprevir—Dizziness—Estradiol—osteoporosis	3.62e-05	0.000245	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—KL—osteoporosis	3.49e-05	0.000343	CbGpPWpGaD
Boceprevir—Vomiting—Estradiol—osteoporosis	3.48e-05	0.000235	CcSEcCtD
Boceprevir—CTSL—Immune System—IRS1—osteoporosis	3.47e-05	0.000341	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IRS1—osteoporosis	3.47e-05	0.000341	CbGpPWpGaD
Boceprevir—Rash—Estradiol—osteoporosis	3.45e-05	0.000233	CcSEcCtD
Boceprevir—Dermatitis—Estradiol—osteoporosis	3.45e-05	0.000233	CcSEcCtD
Boceprevir—Headache—Estradiol—osteoporosis	3.43e-05	0.000232	CcSEcCtD
Boceprevir—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	3.32e-05	0.000326	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IRS2—osteoporosis	3.3e-05	0.000324	CbGpPWpGaD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	3.28e-05	0.000322	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	3.27e-05	0.000321	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL6R—osteoporosis	3.26e-05	0.00032	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL6R—osteoporosis	3.26e-05	0.00032	CbGpPWpGaD
Boceprevir—Nausea—Estradiol—osteoporosis	3.25e-05	0.00022	CcSEcCtD
Boceprevir—CTSS—Immune System—AGER—osteoporosis	3.11e-05	0.000306	CbGpPWpGaD
Boceprevir—CTSS—Immune System—ADCY5—osteoporosis	3.1e-05	0.000305	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IRS1—osteoporosis	2.88e-05	0.000283	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	2.87e-05	0.000281	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ADCY5—osteoporosis	2.73e-05	0.000268	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IRS2—osteoporosis	2.71e-05	0.000267	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL6R—osteoporosis	2.7e-05	0.000265	CbGpPWpGaD
Boceprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	2.68e-05	0.000264	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SPP1—osteoporosis	2.64e-05	0.00026	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—IL6—osteoporosis	2.49e-05	0.000245	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—IL6—osteoporosis	2.49e-05	0.000245	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL1B—osteoporosis	2.48e-05	0.000244	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL1B—osteoporosis	2.48e-05	0.000244	CbGpPWpGaD
Boceprevir—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	2.43e-05	0.000239	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IRS2—osteoporosis	2.39e-05	0.000235	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IRS1—osteoporosis	2.37e-05	0.000233	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL1B—osteoporosis	2.35e-05	0.000231	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—LEP—osteoporosis	2.34e-05	0.00023	CbGpPWpGaD
Boceprevir—CYP3A5—Biological oxidations—POMC—osteoporosis	2.25e-05	0.000221	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	2.25e-05	0.000221	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ESR1—osteoporosis	2.23e-05	0.000219	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL6R—osteoporosis	2.23e-05	0.000219	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PKM—osteoporosis	2.13e-05	0.000209	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—FDPS—osteoporosis	2.13e-05	0.000209	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IRS1—osteoporosis	2.09e-05	0.000205	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—IL6—osteoporosis	2.07e-05	0.000203	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL1B—osteoporosis	2.06e-05	0.000202	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PGLS—osteoporosis	2.01e-05	0.000198	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GPD2—osteoporosis	2.01e-05	0.000198	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—POMC—osteoporosis	2.01e-05	0.000197	CbGpPWpGaD
Boceprevir—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	1.97e-05	0.000194	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL6R—osteoporosis	1.96e-05	0.000193	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IGF1—osteoporosis	1.93e-05	0.00019	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PNP—osteoporosis	1.84e-05	0.000181	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ATIC—osteoporosis	1.84e-05	0.000181	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—TGFB1—osteoporosis	1.83e-05	0.000179	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	1.74e-05	0.000171	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	1.74e-05	0.000171	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	1.72e-05	0.000169	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—TNF—osteoporosis	1.71e-05	0.000168	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—IL6—osteoporosis	1.7e-05	0.000167	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL1B—osteoporosis	1.69e-05	0.000166	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PKM—osteoporosis	1.6e-05	0.000157	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—FDPS—osteoporosis	1.6e-05	0.000157	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—OXCT1—osteoporosis	1.57e-05	0.000154	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CA2—osteoporosis	1.57e-05	0.000154	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MGLL—osteoporosis	1.53e-05	0.00015	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PGLS—osteoporosis	1.52e-05	0.000149	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GPD2—osteoporosis	1.52e-05	0.000149	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	1.5e-05	0.000148	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL6—osteoporosis	1.45e-05	0.000143	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL6—osteoporosis	1.45e-05	0.000143	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ATIC—osteoporosis	1.39e-05	0.000137	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PNP—osteoporosis	1.39e-05	0.000137	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—IDH2—osteoporosis	1.3e-05	0.000127	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP27A1—osteoporosis	1.22e-05	0.00012	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL6—osteoporosis	1.2e-05	0.000118	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ACP5—osteoporosis	1.19e-05	0.000117	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CA2—osteoporosis	1.18e-05	0.000116	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—OXCT1—osteoporosis	1.18e-05	0.000116	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MYC—osteoporosis	1.16e-05	0.000114	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TGFB1—osteoporosis	1.16e-05	0.000114	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MGLL—osteoporosis	1.15e-05	0.000113	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TPI1—osteoporosis	1.1e-05	0.000108	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—POMC—osteoporosis	1.05e-05	0.000103	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—P4HB—osteoporosis	1.04e-05	0.000102	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GAPDH—osteoporosis	1.02e-05	0.0001	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—RAP1A—osteoporosis	9.92e-06	9.74e-05	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL6—osteoporosis	9.92e-06	9.74e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—FDPS—osteoporosis	9.88e-06	9.7e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PKM—osteoporosis	9.88e-06	9.7e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—IDH2—osteoporosis	9.8e-06	9.62e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GPD2—osteoporosis	9.37e-06	9.2e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PGLS—osteoporosis	9.37e-06	9.2e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP27A1—osteoporosis	9.21e-06	9.04e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	9.04e-06	8.88e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	9.02e-06	8.85e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ACP5—osteoporosis	8.96e-06	8.8e-05	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL6—osteoporosis	8.73e-06	8.58e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PNP—osteoporosis	8.57e-06	8.41e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ATIC—osteoporosis	8.57e-06	8.41e-05	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	8.44e-06	8.29e-05	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	8.42e-06	8.27e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TPI1—osteoporosis	8.33e-06	8.18e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ENO1—osteoporosis	8.02e-06	7.88e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PSMA5—osteoporosis	7.9e-06	7.76e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PSMA2—osteoporosis	7.9e-06	7.76e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—P4HB—osteoporosis	7.83e-06	7.69e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GAPDH—osteoporosis	7.69e-06	7.55e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—RAP1A—osteoporosis	7.49e-06	7.35e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CA2—osteoporosis	7.28e-06	7.15e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—OXCT1—osteoporosis	7.28e-06	7.15e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MGLL—osteoporosis	7.1e-06	6.97e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP19A1—osteoporosis	6.41e-06	6.3e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ENO1—osteoporosis	6.05e-06	5.94e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—IDH2—osteoporosis	6.04e-06	5.93e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PSMA2—osteoporosis	5.96e-06	5.86e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PSMA5—osteoporosis	5.96e-06	5.86e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP27A1—osteoporosis	5.68e-06	5.57e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ACP5—osteoporosis	5.52e-06	5.42e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ADCY5—osteoporosis	5.24e-06	5.14e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GPX1—osteoporosis	5.22e-06	5.13e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TPI1—osteoporosis	5.13e-06	5.04e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP19A1—osteoporosis	4.84e-06	4.75e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—P4HB—osteoporosis	4.83e-06	4.74e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTHFR—osteoporosis	4.82e-06	4.73e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GAPDH—osteoporosis	4.74e-06	4.65e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—RAP1A—osteoporosis	4.61e-06	4.53e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ADCY5—osteoporosis	3.95e-06	3.88e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GPX1—osteoporosis	3.94e-06	3.87e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—POMC—osteoporosis	3.85e-06	3.78e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ENO1—osteoporosis	3.73e-06	3.66e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PSMA2—osteoporosis	3.67e-06	3.61e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PSMA5—osteoporosis	3.67e-06	3.61e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTHFR—osteoporosis	3.64e-06	3.57e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.98e-06	2.93e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—POMC—osteoporosis	2.91e-06	2.86e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ADCY5—osteoporosis	2.44e-06	2.39e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GPX1—osteoporosis	2.43e-06	2.38e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTHFR—osteoporosis	2.24e-06	2.2e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—POMC—osteoporosis	1.79e-06	1.76e-05	CbGpPWpGaD
